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Although several proteomic approaches have been used in the search for new lung 
cancer markers, it continues to be the leading cause of cancer related death, mainly due 
to the advanced stage when the neoplasia is diagnosed. Another issue that difficults 
the search for novel markers is the overwhelming presence of high abundant proteins, 
that mask ones that could have a potential role as biomarkers. This inconvenience is 
being addressed with different removal methodologies, that permit an increase in the 
detection capability of potential markers.
In this work we attempt to discover novel markers for non small cell lung cancer 
(NSCLC) performing a prefractionation of the serum with the ProteoPrep 20 Plasma 
Immunodepletion kit (Sigma-Aldrich), that removes the 20 most abundant proteins, 
allowing an enrichment of 20-fold and considerably increasing the possibilities of 
detecting low abundant proteins. The depleted proteomes were then studied by means 
of DIGE methodology.
For this purpose we chose as patients subjects with adenocarcinoma, as this is the 
commonest type of NSCLC in Galicia, in which the malignancy was in early stages 
(localised and regional). As the control group we selected benign subjects with 
pneumonia, based on the higher interest to discriminate between pathologic stages that 
could confuse the diagnosis.
Conventional 2D-PAGE and silver staining were performed to check that effectively 
there was an increase in the resolution of low abundant proteins. Four patients and four 
matched benign controls were then submitted to DIGE, and differences in the expression 
level of the spots were analysed with DeCyder software. The statistical analysis revealed 
twelve proteins differentially expressed between lung cancer and pneumonia subjects, 
eight of them increased and four decreased in the cancer group compared to the control 
individuals. These proteins are being identified by mass spectrometry.
